Table 2.

Cardiovascular variables before, during and after ET-1-induced MCAO

A. Prior to candesartan pretreatment for 7 days; awake
Treatment	MAP	SBP	DBP	PP	HR
Candesartan	87.19 ± 3.74	103.00 ± 4.91	74.82 ± 3.55	28.13 ± 3.54	333.66 ± 10.01
0.9% Saline	92.36 ± 2.36	107.54 ± 1.82	80.35 ± 4.08	27.17 ± 4.22	328.08 ± 14.28
B. After candesartan pretreatment for 7 days; anaesthetized prior to ET-1-induced MCAO
Treatment	MAP	SBP	DBP	PP	HR
Candesartan	80.19 ± 3.25	94.08 ± 2.70	69.35 ± 3.89	24.65 ± 1.80	336.23 ± 9.18
0.9% Saline	83.98 ± 10.01	101.08 ± 8.78	66.51 ± 15.67	35.15 ± 13.65	311.43 ± 10.75
C. Change from baseline during 5 min period after ET-1-induced MCAO; anaesthetized
Treatment	ΔMAP	ΔSBP	ΔDBP	ΔPP	ΔHR
Candesartan	7.89 ± 3.69	8.27 ± 3.69	8.15 ± 3.79	0.47 ± 0.27	19.56 ± 6.99
0.9% Saline	10.57 ± 3.28	9.32 ± 2.42	19.51 ± 11.83	13.17 ± 10.75	27.09 ± 15.66
D. 8 h post ET-1-induced MCAO; awake
Treatment	MAP	SBP	DBP	PP	HR
Candesartan	90.36 ± 6.45	107.06 ± 6.69	77.76 ± 6.60	29.28 ± 2.35	407.21 ± 19.20
0.9% Saline	105.80 ± 21.41	117.77 ± 21.77	96.94 ± 21.20	20.82 ± 3.23	358.96 ± 16.17

All values are reported as means ± S.E.M. (n = 5 rats per treatmentgroup). No significant differences between groups (Student’s unpaired t test). Abbreviations: MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; and HR, heart rate.